Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis | Zendy

Dereck Tait | Zendy; Mark Hatherill | Zendy; Olivier Van Der Meeren | Zendy; Ann M. Ginsberg | Zendy; Elana van Brakel | Zendy; Bruno Salaun | Zendy; Thomas J. Scriba | Zendy; Elaine Jacqueline Akité | Zendy; Helen Ayles | Zendy; Anne Bollaerts | Zendy; MarieAnge Demoitié | Zendy; Andreas H. Diacon | Zendy; Thomas G. Evans | Zendy; Paul Gillard | Zendy; Elizabeth Hellstrӧm | Zendy; James C. Innes | Zendy; Maria Lempicki | Zendy; Mookho Malahleha | Zendy; Neil Martinson | Zendy; Doris Mesia Vela | Zendy; Monde Muyoyeta | Zendy; Videlis Nduba | Zendy; Thierry Pascal | Zendy; Michèle Tameris | Zendy; Friedrich Thienemann | Zendy; Robert J. Wilkinson | Zendy; François Roman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Final Analysis of a Trial of M72/AS01_E Vaccine to Prevent Tuberculosis

Author(s) -

Dereck Tait,

Mark Hatherill,

Olivier Van Der Meeren,

Ann M. Ginsberg,

Elana van Brakel,

Bruno Salaun,

Thomas J. Scriba,

Elaine Jacqueline Akité,

Helen Ayles,

Anne Bollaerts,

MarieAnge Demoitié,

Andreas H. Diacon,

Thomas G. Evans,

Paul Gillard,

Elizabeth Hellstrӧm,

James C. Innes,

Maria Lempicki,

Mookho Malahleha,

Neil Martinson,

Doris Mesia Vela,

Monde Muyoyeta,

Videlis Nduba,

Thierry Pascal,

Michèle Tameris,

Friedrich Thienemann,

Robert J. Wilkinson,

François Roman

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1909953

Subject(s) - immunogenicity , medicine , tuberculosis , pulmonary tuberculosis , mycobacterium tuberculosis , immunology , pathology , immune system

Results of an earlier analysis of a trial of the M72/AS01 E candidate vaccine agains Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without evident safety concerns. We now report the results of the 3-year final analysis of efficacy, safety, and immunogenicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research